Diskussionsleiter: A. Milzi (Aachen), T. Rassaf (Essen)
| (P1931) | Comparison between treatment of "established" versus complex "off-label" coronary lesions with Absorb® bioresorbable scaffold implantation: results from the GABI-R® registry | |
| A. Huseynov, S. Baumann, H. Nef, T. Riemer, S. Schneider, T. Pfannebecker, S. Achenbach, J. Mehilli, T. Münzel, T. Gori, J. Wöhrle, W. Rottbauer, R. Zahn, J. Kastner, A. Schmermund, C. W. Hamm, I. Akin, für die Studiengruppe: GABI-R (Mannheim, Gießen, Ludwigshafen am Rhein, Wetzlar, Erlangen, Bad Berka, Mainz, Ulm, Frankfurt am Main; Wien, AT) | ||
| (P1932) | Predictors of different types of scaffold thrombosis – insights from the German-Austrian ABSORB RegIstRy (GABI-R) | |
| J. Wiebe, J. Kastner, J. Mehilli, T. Gori, C. K. Naber, T. Neumann, G. Richardt, A. Schmermund, J. Wöhrle, R. Zahn, T. Riemer, S. Achenbach, C. W. Hamm, H. Nef (München, Bad Berka, Mainz, Essen, Bad Segeberg, Frankfurt am Main, Ulm, Ludwigshafen am Rhein, Erlangen, Gießen; Wien, AT) | ||
| (P1933) | Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial | |
| H. Rai, F. Alfonso, M. Maeng, C. Bradaric, J. Wiebe, J. Cuesta, E. H. Christiansen, J. Bohner, P. Hoppmann, S. Kufner, R. Colleran, S. Schneider, K.-L. Laugwitz, A. Kastrati, R. Byrne (München, Garmisch-Partenkirchen; Madrid, ES; Aarhus, DK) | ||
| (P1934) | 24-Month Follow-up of Safety & Performance of the second generation Sirolimus-Eluting Bioresorbable Coronary Scaffold (Fantom) – Clinical and angiographic Outcomes of the FANTOM II trial | |
| M. Lutz, J. Weber-Albers, S. Kische, J. Anderson, A. Abizaid, N. Frey, für die Studiengruppe: FANTOM (Kiel, Dortmund, Berlin; San Diego, US; Sao Paulo, BR) | ||
| (P1935) | Two-year clinical outcome of everolimus-eluting versus novolimus-eluting bioresorbable vascular scaffolds in coronary artery disease | |
| F. J. Hofmann, J. Wiebe, O. Dörr, N. F. Boeder, F. Blachutzik, T. Bauer, C. Liebetrau, C. W. Hamm, H. Nef (Gießen, München, Bad Nauheim) | ||
| (P1936) | Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – Results from the Randomized ISAR-Absorb MI Trial | |
| J. Wiebe, S. Schneider, S. Cassese, H. Rai, P. Hoppmann, R. Colleran, F. Alfonso, M. Maeng, E. Kretov, M. Joner, K.-L. Laugwitz, A. Kastrati, R. Byrne (München, Garmisch-Partenkirchen; Madrid, ES; Aarhus, DK; Novosibirsk, RU) | ||
| (P1937) | Long-term results of patients undergoing implantation of everolimus-eluting bioresorbable scaffolds during daily clinical practice – 4-year results of the ISAR Absorb Registry | |
| J. Wiebe, P. Hoppmann, R. Colleran, S. Cassese, R. S. Schmieder, T. Rheude, F. Voll, S. Kufner, M. Joner, K.-L. Laugwitz, A. Kastrati, R. Byrne (München) | ||
| (P1938) | Light attenuation analysis of fully bioresorbable Magnesium scaffolds in a porcine model using optical coherence tomography | |
| T. Koppara, H. Rai, J. Altevogt, P. Zumstein, M. Pritsch, A. Bulin, M. I. Castellanos, M. Joner (München; Bülach, CH) |
